©The Author(s) 2016.
World J Gastrointest Oncol. Feb 15, 2016; 8(2): 222-230
Published online Feb 15, 2016. doi: 10.4251/wjgo.v8.i2.222
Published online Feb 15, 2016. doi: 10.4251/wjgo.v8.i2.222
Table 2 FCGR2A (rs1801274; A > G), FCGR3A (rs366991; T > G) and single nucleotide polymorphism rs61764370 of KRAS 3’ untranslated region genotypes with the correspondent aminoacid change in the 41 metastatic colorectal cancer patients included in this study
| Gene | SNP | Genotype | Aminoacid change | Number of subjects (%) |
| FCGR2A | rs1801274 | A/A | H131H | 14 (34.1%) |
| A/G | H131R | 20 (48.8%) | ||
| G/G | R131R | 7 (17.1%) | ||
| FCGR3A | rs396991 | T/T | F158F | 14 (34.1%) |
| T/G | F158V | 21 (51.2%) | ||
| G/G | V158V | 6 (14.7%) | ||
| KRAS 3’ UTR | rs61764370 | T/T | --- | 32 (78%) |
| T/G | --- | 9 (22%) | ||
| G/G | --- | 0 (0%) |
- Citation: Lo Nigro C, Ricci V, Vivenza D, Monteverde M, Strola G, Lucio F, Tonissi F, Miraglio E, Granetto C, Fortunato M, Merlano MC. Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients. World J Gastrointest Oncol 2016; 8(2): 222-230
- URL: https://www.wjgnet.com/1948-5204/full/v8/i2/222.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v8.i2.222